Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using ctHPV DNA Profile (ReACT)
NCT04900623Phase 2Recruiting
- Start
- Jul 2021
- Primary completion
- Jun 2030
- Modality
- Nanoparticles, DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial in human papillomavirus-positive oropharyngeal squamous cell carcinoma (2 arms). Primary endpoint: Progression-Free Survival at 2 years. Started Jul 2021; status: recruiting.
02
Conditions
human papillomavirus-positive oropharyngeal squamous cell carcinoma
Beyond the preview
Go deeper on NCT04900623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04900623.